The stock of PharmaCyte Biotech Inc (PMCB) has seen a 12.42% increase in the past week, with a 8.38% gain in the past month, and a 10.37% flourish in the past quarter. The volatility ratio for the week is 6.30%, and the volatility levels for the past 30 days are at 5.92% for PMCB. The simple moving average for the past 20 days is 12.36% for PMCB’s stock, with a -0.70% simple moving average for the past 200 days.
Is It Worth Investing in PharmaCyte Biotech Inc (NASDAQ: PMCB) Right Now?
PharmaCyte Biotech Inc (NASDAQ: PMCB) has a price-to-earnings ratio of 3.32x that is above its average ratio. Additionally, the 36-month beta value for PMCB is -0.23. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PMCB is 6.23M and currently, short sellers hold a 0.50% ratio of that float. The average trading volume of PMCB on February 21, 2025 was 16.10K shares.
PMCB) stock’s latest price update
PharmaCyte Biotech Inc (NASDAQ: PMCB) has experienced a rise in its stock price by 12.42 compared to its previous closing price of 1.61. However, the company has seen a gain of 12.42% in its stock price over the last five trading days. businesswire.com reported 2024-05-21 that BALTIMORE–(BUSINESS WIRE)—- $MYMD–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for can.
PMCB Trading at 11.97% from the 50-Day Moving Average
After a stumble in the market that brought PMCB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.84% of loss for the given period.
Volatility was left at 5.92%, however, over the last 30 days, the volatility rate increased by 6.30%, as shares surge +9.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.37% upper at present.
During the last 5 trading sessions, PMCB rose by +12.42%, which changed the moving average for the period of 200-days by -16.20% in comparison to the 20-day moving average, which settled at $1.6109. In addition, PharmaCyte Biotech Inc saw 15.29% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PMCB
The total capital return value is set at -0.11. Equity return is now at value 44.68, with 33.86 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.47.
Conclusion
In conclusion, PharmaCyte Biotech Inc (PMCB) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
